

## Patient Information

|                        |  |
|------------------------|--|
| Username: Aditya       | Latest Lab Pdf: uploads/lab_reports/Aditya_kidney_stone_sa |
| Egfr: 45               | Potassium: 4.2   |
| Sodium: 138            | Serum Creatinine: 1.8                                      |
| Blood Urea: 40         | Has Diabetes: False  |
| Has Hypertension: True | Stage: Stage 3b  |

## Medications & Dosage

| # | Medication Name | Dosage | Frequency | Notes |
|---|-----------------|--------|-----------|-------|
| 1 | wdasd           | 1-0-1  | 3days     |       |

## Clinical Insights

- The patient has CKD Stage 3b with an eGFR of 45 mL/min/1.73m<sup>2</sup>, indicating moderately decreased kidney function. Serum creatinine and blood urea are elevated, consistent with this stage of CKD. Potassium and sodium levels are currently within normal limits. The prescribed medication 'wdasd' is not a recognized pharmaceutical name. Without the specific name of the medication, a detailed clinical analysis regarding its appropriateness, mechanism of action, or specific considerations for CKD Stage 3b cannot be provided. In general, for patients with CKD, medication dosages often need to be adjusted based on the eGFR to prevent accumulation and potential toxicity.

## Risk Assessment

- Given that 'wdasd' is an unknown medication name, a specific risk assessment cannot be performed. However, for any medication prescribed to a CKD patient, there is a general risk of altered drug metabolism and excretion, which can lead to higher drug levels in the body and an increased risk of adverse effects. Potential risks for CKD patients include electrolyte imbalances, worsening kidney function, and other systemic side effects depending on the drug class. The short duration of 3 days might suggest an acute treatment, but without identification, specific risks remain unknown.

## Lifestyle & Care Recommendations

- It is crucial to clarify the exact name of the prescribed medication 'wdasd' with the prescribing healthcare provider or pharmacist. Once the medication is identified, a thorough review should be conducted to ensure its safety and appropriate dosing for a patient with CKD Stage 3b. General recommendations for CKD patients include: always informing healthcare providers about all medications (prescription, over-the-counter, supplements), avoiding nephrotoxic drugs, and ensuring all drug dosages are adjusted according to kidney function. Regular monitoring of kidney function (eGFR, serum creatinine, blood urea) and electrolytes (potassium, sodium) is essential.

## Potential Drug Interactions

- Without a specific medication name, it is impossible to identify any potential drug interactions. Patients with CKD often take multiple medications, increasing the risk of drug-drug interactions. Once the medication is identified, a comprehensive drug interaction screening should be performed, considering all other medications the patient may be taking.

## Recommended Follow-up

- Immediate follow-up with the prescribing physician or pharmacist is recommended to clarify the medication name 'wdasd' and its purpose. Regular follow-up appointments for CKD management are essential, typically every 3-6 months for Stage 3b, which should include a comprehensive medication review and monitoring of kidney function and electrolyte levels.

### MEDICAL DISCLAIMER

*This report is generated using AI analysis of provided prescription data. It is intended for informational and educational purposes only. This analysis does NOT constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.*